Class / Patent application number | Description | Number of patent applications / Date published |
514510000 | Polycyclo ring system | 83 |
20090030075 | Remedy for and Method of Treating Ischemic Cerebral Stroke - A drug for alleviating bleeding tendency caused by a thrombus removing means comprising, as an active ingredient, a compound represented by formula (I): | 01-29-2009 |
20090036524 | TRITERPENE DERIVATIVES FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE BY INHIBITION OF NF-KAPPAB - The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF- | 02-05-2009 |
20090088472 | Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient - An object of the present invention is to provide a protective agent for a neuronal cell. The protective agent for a neuronal cell according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, R | 04-02-2009 |
20090182045 | USE OF AMINAPHTONE FOR THE PREPARATION OF A MEDICAMENT FOR TREATING ARTERIOPATHIES - The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration. | 07-16-2009 |
20090186940 | Synthesis of Scabronines and Analogues Thereof - A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided. | 07-23-2009 |
20090292016 | Stable Pharmaceutical Compositions Containing Pravastatin - Stabilized pharmaceutical preparations containing a drug which is sensitive to a low pH environment, such as pravastatin are disclosed in which pravastatin degradations is prevented with a buffering agent. The basic excipient enhances storage stability. | 11-26-2009 |
20090306203 | PLEUROMUTILIN DERIVATIVES CONTAINING A HYDROXYAMINO- OR ACYLOXYAMINOCYCLOALKYL GROUP - The present invention relates to Compounds of general formula (I), wherein R is hydrogen and R | 12-10-2009 |
20100035983 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 02-11-2010 |
20100120907 | DERIVATIVES OF AMYRIS ALCOHOLS AND EUDESMOL FOR TREATING COLD SORES AND HERPES - Provided are topical formulations comprising an Amyris alcohol and/or ester derivatives of Amyris alcohol which may be used for the treatment of diseases including herpes virus infection (e.g., HSV-1, HSV-2), epidermoid carcinoma, cold sores, and human papillomavirus. Amyris alcohols contemplated for use with the present invention include valerianol, beta-eudesmol, epi-gamma-eudesmol, elemol, alpha-eudesmol, and ester derivatives thereof. | 05-13-2010 |
20100168231 | TARGET ENZYME FOR THE TREATMENT OF ACNE - The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea. | 07-01-2010 |
20100173989 | ANTIWRINKLE AGENT AND SKIN COSMETIC COMPOSITION - The present invention provides an antiwrinkle agent and skin cosmetic composition having excellent alleviating effects on wrinkles appearing due to aging, and especially at exposed locations of skin, and a high degree of safety. | 07-08-2010 |
20110009485 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF - A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided. | 01-13-2011 |
20110009486 | METHOD FOR TREATING PRURITUS BY ADMINISTERING FULLERENES - Disclosed herein are methods of treating pruritus in a subject in need thereof. A method of treating pruritus comprises administering a therapeutically effective amount of fullerenes to a subject in need thereof. | 01-13-2011 |
20110054021 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 03-03-2011 |
20110065788 | AQUEOUS FORMULATIONS OF (2-HYDROXYMETHYL-INDANYL-4-OXY)-PHENYL-4,4,4-TRIFLUOROBUTANE-1-SULFONATE - The invention relates to aqueous formulations containing (−)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions. | 03-17-2011 |
20110077297 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND HYPERKERATOTIC LESIONS - A method of treating inflammation and hyperkeratotic lesions in a mammal in need thereof, by administering the following compound (NVX-207), a related compound, or a pharmaceutically acceptable salt thereof to the mammal. | 03-31-2011 |
20110281944 | METHOD OF A RHEIN COMPOUND FOR INHIBITING PANCREATIC ISLET BETA-CELL DYSFUNCTION AND PREVENTING OR TREATING A PANCREATIC ISLET BETA-CELL DYSFUNCTION RELATED DISORDER - This invention provides a method for inhibiting pancreatic islet β-cell dysfunction, comprising administering to a subject in need thereof an inhibitory effective amount of a rhein compound having the general formula (I) or a pharmaceutically acceptable salt thereof, | 11-17-2011 |
20110288169 | TRITERPENOID COMPOUNDS AND METHODS OF USE THEREOF - The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors. | 11-24-2011 |
20120010284 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS - The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure. | 01-12-2012 |
20120022155 | USE OF AMINAPHTONE FOR THE PREPARATION OF A MEDICAMENT FOR TREATING ARTERIOPATHIES - The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration | 01-26-2012 |
20120022156 | DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME - Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl. | 01-26-2012 |
20120129925 | SHIP 1 MODULATORS - The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof. | 05-24-2012 |
20120129926 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF - The invention relates to novel calcium-sensing receptor (CaSR) modulating trifluoromethylphenylene cyclopentylene compounds represented in formula (I) and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments. | 05-24-2012 |
20120129927 | New Anthraquinone Derivatives - The invention relates to two novel substances, namely (1R,2S,3S,4R)-3-acetoxy-1,2,4,5-tetrahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydroanthracene-9,10-dione (3-O-acetyl altersolanol M) | 05-24-2012 |
20120220652 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease - The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis. | 08-30-2012 |
20120238623 | Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists - The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection. | 09-20-2012 |
20120259007 | ANTICOAGULANT COMPOUNDS AND THEIR USE - According to the invention there is provided a compound of formula (I): wherein R | 10-11-2012 |
20120316234 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF - The present invention is related to an anthraquinone-based compound represented by compound (I) | 12-13-2012 |
20130030050 | TREATMENT OF OSTEOPOROSIS - According to the invention there is provided a compound of formula (I): wherein R | 01-31-2013 |
20130109752 | DERIVATIVE OF 18beta-GLYCYRRHETINIC ACID APT TO SUPPRESS CANCER CELLS | 05-02-2013 |
20130190395 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS - The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection. | 07-25-2013 |
20130197079 | MGLU 2/3 AGONISTS - The present invention provides novel mGlu2/3 agonists useful in the treatment of neurological or psychiatric disorders. | 08-01-2013 |
20130303607 | Triterpenoids and Compositions Containing the Same - The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin. | 11-14-2013 |
20130324599 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF - The present invention relates generally to the compound:
| 12-05-2013 |
20140045936 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE - The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein. | 02-13-2014 |
20140107194 | COMPOUNDS FOR USE IN THE TREATMENT OF IMMUNE RELATED INFLAMMATORY DISEASE - Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the formula: wherein R is selected from one or more of the same or different of hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted aryl, alkoxy, aryloxy, thiol, and optionally substituted amino, and wherein R | 04-17-2014 |
20140206762 | Compositions And Methods Of Use Of Phorbol Esters - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects. | 07-24-2014 |
20140235711 | DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME - Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl. | 08-21-2014 |
20140309300 | Bicyclic Labdane Diterpenes for Use in the Treatment of TRPC6 Associated Diseases - The present invention relates to bicyclic labdane diterpenes for use in the treatment of a disease associated with activation of transient receptor potential cation channel 6 (TRPC6), preferably a pulmonary or a renal disease. In one aspect the invention relates to the use of a bicyclic labdane diterpene for blocking calcium transport via TRPC6. Another aspect of the invention is a bicyclic labdane diterpene according to formula (1) for use as a medicament wherein R | 10-16-2014 |
20140323567 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS - Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure: | 10-30-2014 |
20140350100 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS - The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor. | 11-27-2014 |
20140357711 | Amooranin Compounds and Analogs Thereof and Related Methods of Use - Methods for synthesizing amooranin (25-hydroxy-3-oxoolean-12-en-28-oic acid (AMR) and/or amooranin analogs, including amooranin methyl ester (AMR-Me), by using oleanolic acid in an oxidation process, and therapeutic uses thereof are described. | 12-04-2014 |
20140364492 | PHORBOL TYPE DITERPENE COMPOUND, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF VIRAL INFECTIOUS DISEASES INCLUDING SAME - The present invention relates to a diterpene compound derived from | 12-11-2014 |
20150011626 | METHODS OF TREATING AND PREVENTING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM - Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammatory agent to the patient. Examples of the anti-inflammatory agent include glutathione and inhibitors of purinergic receptors such as P2X | 01-08-2015 |
20150011627 | TRITERPENOIDS AND COMPOSITIONS CONTAINING THE SAME - The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin. | 01-08-2015 |
20150080465 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF - The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof. | 03-19-2015 |
20150141506 | INDANE DIMERS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE - Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the absolute stereochemistry and formula: | 05-21-2015 |
20150148414 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C | 05-28-2015 |
20150306110 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND HYPERKERATOTIC LESIONS - A method of treating inflammation and hyperkeratotic lesions in a mammal in need thereof, by administering the following compound, a related compound, or a pharmaceutically acceptable salt thereof to the mammal: | 10-29-2015 |
20150337005 | ESTERS OF GLYCYRRHETINIC ACID, PREPARATION AND COSMETIC APPLICATIONS THEREOF - An ester of glycyrrhetinic acid with (poly)glycerol-sorbitol and cosmetic compositions thereof is described. The introduction of sorbitol in the (poly)glycerol chain determines an increase in solubility of the ester of the invention increasing solubility in water and the possibility of using glycyrrhetinic acid in cosmetic applications. | 11-26-2015 |
20150342917 | Autoimmune Disorder Treatment Using RXR Agonists - The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection. | 12-03-2015 |
20160051505 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS - This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. | 02-25-2016 |
20160106698 | Compositions And Methods Of Use Of Phorbol Esters - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects. | 04-21-2016 |
20160120833 | COMPOSITION AND METHOD FOR TREATING AND RELIEVING MYOPIA - The present invention provides a pharmaceutical composition for treating and/or relieving myopia, the pharmaceutical composition comprises a therapeutically effective amount of an anti-inflammatory agent and a pharmaceutically acceptable carrier; the pharmaceutical composition of the present invention is safe, and can treat and/or relieve myopia by the anti-inflammatory agent. The pharmaceutically acceptable carrier can effectively encapsulate the anti-inflammatory agent at a specific ratio, and the stability and solubility of the pharmaceutical composition can be enhanced. | 05-05-2016 |
514511000 | Two of the cyclos share at least three ring members (i.e., bridged) | 29 |
20090292017 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 11-26-2009 |
20100048698 | MACROCYCLIC DITERPENES FOR TREATING CONDITIONS ASSOCIATED WITH PROTEIN KINASE C - The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species. The present invention further contemplates a method for the prophylaxis or treatment of mammalian, animal or avian subjects for inflammatory conditions including chronic or transitory inflammatory conditions or for ameliorating the symptoms of an inflammatory condition by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Fuphorbiaceae family or botanical or horticultural relatives thereof or a derivative, chemical analogue or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or be in the form of a chemical fraction, sub-fraction or preparation or extract of the plant. | 02-25-2010 |
20100204318 | TREATMENT OF VIRALLY INDUCED LESIONS - The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma virus, such as a mammalian papilloma virus, in particular a Human Papilloma Virus. | 08-12-2010 |
20100240746 | STEREOISOMERS OF TRICYCLODECAN-9-YL-XANTHOGENATE - Provided herein are optically active stereoisomers of tricylclodecan-9-yl xanthogenate, processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease caused by a virus. | 09-23-2010 |
20110257262 | CRYSTALLINE INGENOL MEBUTATE - The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC). | 10-20-2011 |
20120035260 | TELLURIUM-CONTAINING COMPOUNDS FOR AFFECTING FEMALE'S REPRODUCTIVE SYSTEM FOLLOWING CHEMOTHERAPY AND/OR RADIOTHERAPY - Use of tellurium-containing compounds in a method of conception and/or for maintaining and/or augmenting fertility in female following chemotherapy and/or radiotherapy is disclosed. The tellurium-containing compound is utilized in combination with a chemotherapeutic agent and/or radiation, such that the female treated by the chemotherapeutic agent and/or radiation and by the tellurium-containing compound is instructed to refrain from conceptive sex for a pre-determined time period, following the chemotherapy and/or radiotherapy, during which conception is undesired. The tellurium-containing compound is utilized in combination with a chemotherapeutic agent and/or radiation, such that the female treated by the chemotherapeutic agent and/or radiation and by the tellurium-containing compound is instructed to refrain from sex and/or from reproduction for a pre-determined time period, and is then allowed to practice reproduction. | 02-09-2012 |
20120295970 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 11-22-2012 |
20120295971 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 11-22-2012 |
20120309827 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 12-06-2012 |
20130079400 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS - Process for the preparation of a compound of formula I | 03-28-2013 |
20130158110 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 06-20-2013 |
20130225677 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 08-29-2013 |
20130225678 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 08-29-2013 |
20130225679 | ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS - Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided. | 08-29-2013 |
20130274329 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES - Compounds selected from the group of N-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C | 10-17-2013 |
20130324600 | INGENOL-3-ACYLATES I - The invention relates to compounds of general formula (I) wherein R is (C | 12-05-2013 |
20130331446 | 3-ACYL-INGENOLS II - The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis. | 12-12-2013 |
20140249218 | ADMINISTRATION OF INGENOL MEBUTATE - The present invention relates to novel crystalline forms of ingenol ingenol-3-angelate and methods of preparation and use thereof. More specifically, the invention relates to a novel crystalline form and purified forms of the compound of Formula 1 (ingenol-3-mebutate; ingenol-3-angelate; isoform ‘b’; PEP005), which is characterized by, for example, attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy, single crystal X-Ray crystallography (XRC), X-ray powder diffraction, and, Differential Scanning Calorimetry (DSC), and methods of preparation and use thereof. | 09-04-2014 |
20140275245 | BICYCLIC ANALGESIC COMPOUNDS - Analgesic compounds for treatment of pain or fever, comprising a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering the compounds. | 09-18-2014 |
20140343141 | TOPICAL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SURFACTANT-COSOLVENT MIXTURE - A topical composition for cutaneous application which is a water-in-oil emulsion comprises an oily phase comprising (a) an ingenol derivative in dissolved form; (b) at least one non-ionic surfactant selected from the group consisting of polyoxyl glycerides, polyoxyethylene castor oil derivatives, polyoxyethylene alkyl ethers, polysorbates, or a mixture of acrylamide acryloyldimethyl taurate copolymer, isohexadecane and polysorbate 80, sterols, fatty alcohols, fatty acid phosphonates, mono- or diglycol esters, mono- di- or polyglyceryl esters, mono-, di- or plyglucose esters, sucrose esters or sorbitan esters, the non-ionic surfactant being present in an amount of from about 0.5% by weight to about 10% by weight of the composition; (c) a solvent for the ingenol derivative; and an aqueous phase buffered to a pH of 2.6-3.7. | 11-20-2014 |
20140350101 | GEL COMPOSITIONS - Substantially anhydrous topical gel compositions comprising a homogeneous mixture of: (a) ingenol-3-angelate in dissolved form; and (b) anon-aqueous carrier. | 11-27-2014 |
20140357712 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 12-04-2014 |
20150025139 | INGENOL MEBUTATE IN COMBINATION WITH CRYOTHERAPY FOR THE TREATMENT OF ACTINIC KERATOSIS - The invention relates to the treatment of actinic keratosis (AK) lesions using sequential cryotherapy and field treatment with ingenol mebutate (e.g., PEP005 Gel). | 01-22-2015 |
20150133542 | METHOD OF TOPICALLY TREATING ACTINIC KERATOSIS WITH INGENOL MEBUTATE CYCLE THERAPY - The present invention relates to cyclic or repeated use of the ingenol mebutate for topical treatment of actinic keratosis lesions. Generally speaking, the present invention comprises a first ingenol mebutate treatment cycle and a second ingenol mebutate treatment cycle, wherein the first treatment cycle topically treats a treatment area with a topical gel formulated with ingenol mebutate at a selected dosage strength for a specified treatment regimen, and the second ingenol mebutate treatment cycle comprises topically re-treating the treatment area with the same topical ingenol mebutate gel for the same specified treatment regimen, if following the first treatment cycle, the treatment area failed to clear or failed to remain clear of AK lesions. The present invention further relates to spot or individual lesion therapy in the treatment area following the topical bi-cyclic therapy with ingenol mebutate. | 05-14-2015 |
20150133543 | TOPICAL GEL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SOLVENT MIXTURE - A substantially anhydrous pharmaceutical gel composition for cutaneous application comprising an ingenol derivative in dissolved or solubilized form, a solvent mixture of
| 05-14-2015 |
20150315124 | INGENOL-DERIVED COMPOUNDS THAT CAN BE USED FOR TREATING CANCER - The present invention relates to new ingenol derivative compounds for treating cancer. In other aspects, the invention relates to a pharmaceutical composition, medicament, method for treating cancer and dosage form. | 11-05-2015 |
20150359774 | ACTIVE FRACTION OF A POLAR SOLVENT EXTRACT FROM THE LATEX OF EUPHORBIACEAE PLANTS - The present invention generally refers to an active fraction of an extract of the latex of plants from the family Euphorbiaceae in a polar solvent, as well as of one or more compounds contained therein, as well as the use of said fraction and/or said compounds, particularly in the treatment of cancer. The invention also refers to compositions comprising said active fraction and/or said compounds, as well as their use for the treatment of diseases concerning cell proliferation/angiogenesis, particularly cancer. | 12-17-2015 |
20160120835 | A TOPICAL COMPOSITION - The invention provides a topical composition for cutaneous application which is an oil-in-water emulsion comprising (a) an oily phase, (b) an ingenol derivative in dissolved form; (c) an aqueous phase buffered to a p H of below 4.5, (d) at least one surfactant. | 05-05-2016 |
20160128965 | GEL COMPOSITIONS - Novel aqueous topical gel compositions comprising ingenol-3-angelate. | 05-12-2016 |